The short version of lyophilized powder fits in a sentence. The long version — which is the one that helps — is below.
This page was last updated on 2026-06-07 and is reviewed periodically as new material appears.
AOD-9604 has been investigated primarily as a potential treatment for obesity and related metabolic conditions. Early laboratory work examined its effects on fat cells, and later studies moved into animal models and human clinical trials. Some trials reportedly reached Phase II, but the program did not lead to an approved medicine. Published summaries often note that weight-loss results were modest or inconsistent. The full trial data are not all publicly available in detail.
Regulatory treatment of AOD-9604 has varied. In sports anti-doping, the peptide became widely discussed during a 2013 investigation into an Australian professional sports club. Authorities at the time debated whether it fell under prohibitions on growth hormone and related substances. Later clarifications and updated lists have addressed the compound in different ways. Anyone seeking current status should consult the latest applicable rules, and commercial supply for human use is not authorized in major markets.
Research interest in AOD-9604 often focuses on whether it can influence lipid metabolism without the growth-promoting or glucose-related effects of full-length hGH. This question remains unresolved, and findings depend on model, dose, and measurement method. Some reviews treat the peptide as a historical obesity candidate rather than an active therapeutic. Others cite it in discussions of peptide fragments, metabolic signaling, and performance-enhancing substances. Clear conclusions are limited by the small number of rigorous, independent human studies.
Proposed mechanism focuses on lipolysis, the breakdown of stored triglycerides into free fatty acids and glycerol. AOD-9604 is thought to act on adipose tissue without stimulating appetite or affecting blood sugar in the same way as growth hormone. Laboratory studies report increased fat oxidation in some models. The precise receptor interactions and signaling pathways remain incompletely characterized. Researchers have proposed that the peptide may influence fat mobilization through pathways distinct from the full hormone.
Research has examined whether the peptide affects fat mass independently of growth hormone's other actions. Early animal studies suggested reductions in body fat, but species differences and small sample sizes limit interpretation. Human studies have generally been short and have not consistently shown large effects. Some trials measured body composition, lipid profiles, and safety parameters, but the overall picture is one of suggestive yet inconclusive metabolic activity. Findings vary across study populations and protocols.
| Property | Value | Notes |
|---|---|---|
| Primary research area | Obesity and metabolic regulation | Studied in cell, animal, and human models |
| Highest reported trial phase | Phase II | Public summaries describe mixed results |
| Common route in trials | Subcutaneous injection | Typical for peptide therapeutics |
| Regulatory example | 2013 Australian anti-doping review | Classification was debated at the time |
| Approval status | Not approved as a human medicine | Status can change by jurisdiction |
AOD9604 is commonly supplied as a white to off-white lyophilized powder. The powder is typically stored at -20 °C or below, protected from light and moisture, because peptides can degrade through oxidation, hydrolysis, or aggregation. If it is reconstituted for laboratory use, an appropriate aqueous buffer or solvent is chosen, and the solution is kept cold and handled to avoid repeated freeze-thaw cycles. These practices support stability but do not imply suitability for human use.
Identity and purity are usually assessed with reversed-phase high-performance liquid chromatography and mass spectrometry. Reversed-phase HPLC separates the peptide from related impurities and can estimate purity by ultraviolet absorbance, while mass spectrometry confirms the molecular mass and detects modifications. Peptide mapping, amino acid analysis, and disulfide mapping may be used when the sequence or disulfide arrangement must be verified. Because AOD9604 contains cysteine residues, oxidation and disulfide isomers are possible quality concerns in synthetic batches.
Analytical characterization of AOD-9604 typically employs reversed-phase high-performance liquid chromatography (RP-HPLC) to assess purity and identity. Mass spectrometry provides confirmation of molecular mass, while amino acid analysis can verify composition. These methods are standard for peptide research chemicals. Because the peptide lacks a distinct chromophore, detection often relies on ultraviolet absorbance at 214 nm or mass spectrometric response. Laboratories may also use capillary electrophoresis for separation. For example, size-exclusion chromatography can detect aggregates.
Stability of AOD-9604 depends on storage conditions. Lyophilized powder is generally more stable than reconstituted solution. Recommended storage is typically at -20°C or lower, protected from light and moisture. Repeated freeze-thaw cycles can cause aggregation or degradation. In solution, the peptide may be susceptible to hydrolysis or oxidation, so aliquoting and cold storage are common practices. Researchers often add stabilizers such as mannitol or trehalose during lyophilization to improve shelf life.
AOD-9604 is a synthetic peptide whose structure corresponds to a C-terminal segment of human growth hormone. It is often described as hGH fragment 176-191, a 16-amino-acid sequence. The peptide was designed to isolate a region of hGH associated with fat metabolism while avoiding the full hormone's growth-promoting actions. Laboratory and commercial materials typically present it as a lyophilized powder for research use. Its identity is defined by amino acid sequence, not by a single brand.
The fragment includes residues that can form an internal disulfide bond between two cysteine positions. This structural feature can influence how the peptide folds and how stable it is in solution. AOD-9604 differs from full-length hGH in size and receptor interactions; it does not contain the entire growth hormone sequence. Published descriptions sometimes use slightly different residue numbering, so sequence information should be checked against primary sources. The molecule is small compared with intact hGH, which affects analytical detection and purification approaches.
Choriogonadotropin subunit beta (CG-beta) also known as chorionic gonadotrophin chain beta is a protein that in humans is encoded by the CGB gene. This gene is a member of the glycoprotein hormone beta chain family and encodes the beta 3 subunit of chorionic gonadotropin (CG). Glycoprotein hormones are heterodimers consisting of a common alpha subunit and a unique beta subunit which confers biological specificity. CG is produced by the trophoblastic cells of the placenta and stimulates the ovaries to synthesize the steroids that are essential for the maintenance of pregnancy. The beta subunit of CG is encoded by 6 genes which are arranged in tandem and inverted pairs on chromosome 19q13.3 and contiguous with the luteinizing hormone beta subunit gene.
=== April === 2 April – The Birmingham Walkathon returns to the city for the first time since 2013. The event, originally organised by Birmingham radio station BRMB, is organised for its 2023 staging by former BRMB director David Bagley and charity Help Harry Help Others. 3 April – NHS England launches its spring booster campaign, which will see around five million people, including those aged over 75 or classed as clinically vulnerable, receive a COVID-19 booster vaccine. The National Education Union announces two further strike dates in England on 27 April and 2 May, stating that the offer from the pay UK government is unacceptable, not fully funded, and does not address a shortage of teachers. Environment Minister Therese Coffey confirms government plans to ban wet wipes containing plastic in England as a means of helping to tackle water pollution. The new England women's national football team kit is unveiled, and it is confirmed they will wear blue shorts at the 2023 World Cup. The change has been made amid period concerns. 4 April – Members of the Association of School and College Leaders overwhelmingly reject the UK government's 4.3% pay offer for teachers in England. 5 April – Twenty one people are convicted over the largest child sex abuse case ever investigated by West Midlands Police. The National Association of Head Teachers becomes the third teaching union to reject the UK government's 4.3% pay offer for teachers in England.
In response, Cottrell went on to establish an independent nonprofit organization on 26 February 1912 — the Research Corporation for Science Advancement — not only to manage his own patents, but to "contract with various universities, industry workers, and unattached inventors in order to manage their patents", with the profits used to fund research, regardless of the applicant's university. In 1925, Harry Steenbock, a professor of biochemistry at the University of Wisconsin–Madison, offered to assign his thyroxine patent rights (HS.1) to the university. The university's Regents declined Steenbock's offer. In response, the Wisconsin Alumni Research Foundation (WARF), an independent University technology transfer office, was created to manage Steenbok's patent; and, by 2023, WARF had gone on to manage more than 4,200 patents (with 2,200 patents still active). For Robertson, the need for appropriate buildings, laboratories, supplies, and equipment to be funded for research was always at least as important as the funding of any individual researcher. In 1917, in a precedent-setting action, Robertson proposed assigning his patent rights to the University of California (EN.1; SC.1) (i.e., rather than Cottrell's non-specific Research Corporation) specifically to support medical research at the University of California.
Sources: en.wikipedia.org
An association between osteoporosis, another disease characterized by the degradation of bony tissue, and sarcopenia, the age-related degeneration of muscle mass and quality have also been found. Whether this link is a result of direct regulation or a secondary effect through muscle mass is not known. A link in mice between the concentration of myostatin in the prenatal environment and the strength of offspring's bones, partially counteracting the effects of osteogenesis imperfecta (brittle bone disease) has been found. Osteogenesis imperfecta is due to a mutation that causes the production of abnormal Type I collagen. Mice with defective myostatin were created by replacing sequences coding for the C-terminal region of myostatin with a neomycin cassette, rendering the protein nonfunctional. By crossbreeding mice with the abnormal Type I collagen and those with the knockout myostatin, the offspring had "a 15% increase in torsional ultimate strength, a 29% increase in tensile strength, and a 24% increase in energy to failure" of their femurs as compared to the other mice with osteogenesis imperfecta, showing the positive effects of decreased myostatin on bone strength and formation.
=== Death of Torrijos === After the Nicaraguan Revolution was launched by the Sandinistas against U.S.-backed authoritarian ruler Anastasio Somoza Debayle in August 1978, Torrijos and Noriega initially supported the rebels, providing them with surplus National Guard equipment and allowing Panama to be used as a cover for arms shipments from Cuba to Nicaragua. Torrijos sought for himself the same aura of "democratic respectability" that the Sandinista rebels had in Nicaragua, and so abandoned the title of "Maximum Leader" he had taken in 1972, promising that elections would be held in 1984. Noriega also arranged for weapons purchased in the U.S. to be shipped to the Sandinista forces, a deal on which he made a profit. The U.S. discovered Noriega's role in supplying weapons, and though the episode proved embarrassing to the Carter administration in the U.S., no charges were brought against Noriega because the U.S. did not wish to anger a friendly government, and the issue was rendered moot by the Sandinista victory in 1979. After Somoza's overthrow, Noriega continued to smuggle weapons, selling them to leftist guerrillas fighting the U.S.-backed authoritarian government in El Salvador. After one of these shipments was captured, Torrijos, who had friends in the Salvadoran military government, reprimanded Noriega, though the shipments did not stop altogether. Torrijos died in a plane crash on July 31, 1981.
=== Immunomodulation === Interferon, in the form of interferon gamma-1b (Actimmune) is approved by the Food and Drug Administration for the prevention of infection in CGD. It has been shown to reduce infections in CGD patients by 70% and to decrease their severity. Although its exact mechanism is still not entirely understood, it has the ability to give CGD patients more immune function and therefore, greater ability to fight off infections. This therapy has been the standard treatment for CGD for several years.
Sources: en.wikipedia.org
The role of gastric acid in digestion was established in the 1820s and 1830s by William Beaumont on Alexis St. Martin, who, as a result of an accident, had a fistula (hole) in his stomach, which allowed Beaumont to observe the process of digestion and to extract gastric acid, verifying that acid played a crucial role in digestion.
In early 1902, British tactics of containment, denial, and harassment finally began to yield results against the Boer guerrillas. The sourcing and co-ordination of intelligence became increasingly efficient with regular reporting from observers in the blockhouses, from units patrolling the fences and conducting "sweeper" operations, and from native Africans in rural areas who increasingly supplied intelligence, as the Scorched Earth policy took effect and they found themselves competing with the Boers for food supplies. Kitchener's forces at last began to affect the Boers' fighting strength and freedom of manoeuvre, and made it harder for the Boers and their families to survive. Despite this success, almost half the Boer fighting strength, around 15,000 men, were still in the field fighting by May 1902. However, Kitchener's tactics were costly: Britain was running out of time, patience, and money needed for the war. The British offered terms of peace on various occasions, notably in March 1901, but all them were rejected by Botha and the "Bitter-enders" among the Boers, who pledged to fight until the bitter end and rejected the demand for surrender or any compromise made by the "Hands-uppers". Their reasons included their hatred of the British, loyalty to their dead comrades, solidarity with fellow Boer commandos, a desire for independence, religious arguments, and fear of captivity or punishment. On the other hand, their women and children were dying in prison camps every day, and independence seemed more and more impossible.
Bone morphogenetic proteins (BMPs) are a group of growth factors also known as cytokines and as metabologens. Professor Marshall Urist and Professor Hari Reddi discovered their ability to induce the formation of bone and cartilage, BMPs are now considered to constitute a group of pivotal morphogenetic signals, orchestrating tissue architecture throughout the body. The important functioning of BMP signals in physiology is emphasized by the multitude of roles for dysregulated BMP signalling in pathological processes. Cancerous disease often involves misregulation of the BMP signalling system. Absence of BMP signalling is, for instance, an important factor in the progression of colon cancer, and conversely, overactivation of BMP signalling following reflux-induced esophagitis provokes Barrett's esophagus and is thus instrumental in the development of esophageal adenocarcinoma. Recombinant human BMPs (rhBMPs) are used in orthopedic applications such as spinal fusions, nonunions, and oral surgery. rhBMP-2 and rhBMP-7 are Food and Drug Administration (FDA)-approved for some uses. rhBMP-2 causes more overgrown bone than any other BMPs and is widely used off-label.
Sources: en.wikipedia.org
No major medicines regulator appears to have approved AOD-9604 for human therapeutic use. It has been studied in clinical trials, but those programs did not result in a marketed drug.
It became prominent during a 2013 Australian sports investigation that examined whether it was a prohibited growth-hormone-related substance. Subsequent interpretations and list updates have varied, so current rules should be checked directly.
Published summaries generally report limited or inconsistent weight-loss effects, and complete trial data are not widely available. The studies were not sufficient to establish it as an effective obesity treatment.
It is proposed to promote lipolysis in fat tissue, the breakdown of stored fat into fatty acids and glycerol. The detailed receptor and signaling mechanisms are not fully established.